This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Woodworth, C. D. Articles by DiPaolo, J. A. Search for Related Content PubMed PubMed Citation Articles by Woodworth, C. D. Articles by DiPaolo, J. A.

Leukoregulin and -Interferon Inhibit Human Papillomavirus Type 16 Gene Transcription in Human Papillomavirus-immortalized Human Cervical Cells

Laboratory of Biology [C. D. W., S. S., C. H. E., J. A. D.] and Laboratory of Cellular Carcinogenesis and Tumor Promotion [U. L.], Division of Cancer Etiology, National Cancer Institute, Bethesda, Maryland 20892

The human papillomavirus (HPV) transforming genes E6 and E7 are retained and expressed in the majority of cervical cancers implying an important role for these proteins in maintenance of the malignant phenotype. Leukoregulin (LR) and recombinant -interferon (r-IFN), lymphokines secreted by immune cells present in regressing HPV infections, inhibited transcription of E6/E7 RNAs in several human cervical epithelial cell lines immortalized by recombinant HPV-16, -18, and -33 DNAs. r-IFN was not effective. Reduction in E6/E7 RNA expression was accompanied by inhibition of cell proliferation coincident with an increase in epidermal transglutaminase activity, a marker of squamous differentiation. LR and r-IFN enhanced transcription of class 1 cell surface histocompatibility antigens (HLA) and r-IFN additionally induced HLA class 2 expression. HPV-immortalized cells developed partial resistance to the growth inhibitory effects of lymphokines after malignant transformation or extended propagation in culture. This is the first demonstration that LR and r-IFN selectively inhibit transcription of HPV-transforming genes and suggests a molecular mechanism by which these lymphokines participate in regression of premalignant cells.

¹ To whom requests for reprints should be addressed, at the National Cancer Institute, Laboratory of Biology, Division of Cancer Etiology, Building 37, Room 2A19, Bethesda, MD 20892.

Received 4/ 9/91. Accepted 11/ 1/91.

This article has been cited by other articles:

				J. Palefsky Biology of HPV in HIV Infection Adv. Dent. Res., April 1, 2006; 19(1): 99 - 105. [Abstract] [Full Text] [PDF]

				S.-J. Lee, Y.-S. Cho, M.-C. Cho, J.-H. Shim, K.-A. Lee, K.-K. Ko, Y. K. Choe, S.-N. Park, T. Hoshino, S. Kim, et al. Both E6 and E7 Oncoproteins of Human Papillomavirus 16 Inhibit IL-18-Induced IFN-{{gamma}} Production in Human Peripheral Blood Mononuclear and NK Cells J. Immunol., July 1, 2001; 167(1): 497 - 504. [Abstract] [Full Text] [PDF]

				M. Scott, M. Nakagawa, and A.-B. Moscicki Cell-Mediated Immune Response to Human Papillomavirus Infection Clin. Vaccine Immunol., March 1, 2001; 8(2): 209 - 220. [Full Text] [PDF]

				H. z. Hausen Papillomaviruses Causing Cancer: Evasion From Host-Cell Control in Early Events in Carcinogenesis J Natl Cancer Inst, May 3, 2000; 92(9): 690 - 698. [Abstract] [Full Text] [PDF]

				K. Y. Kim, L. Blatt, and M. W. Taylor The effects of interferon on the expression of human papillomavirus oncogenes J. Gen. Virol., March 1, 2000; 81(3): 695 - 700. [Abstract] [Full Text]

				H. Bontkes, T. de Gruijl, J. Walboomers, J. Schiller, J Dillner, T. Helmerhorst, R. Verheijen, R. Scheper, and C. Meijer Immune responses against human papillomavirus (HPV) type 16 virus-like particles in a cohort study of women with cervical intraepithelial neoplasia. II. Systemic but not local IgA responses correlate with clearance of HPV-16 J. Gen. Virol., February 1, 1999; 80(2): 409 - 417. [Abstract]

				C. Evans Cytokines and viral anti-immune genes Stem Cells, March 1, 1996; 14(2): 177 - 184. [Abstract]